This page summarizes R&D investment signals for DNA damage repair therapies in neurodegenerative diseases. DNA repair decline is a key feature of aging and neurodegeneration, with impaired repair mechanisms contributing to neuronal dysfunction and cell death in Alzheimer's Disease, Parkinson's Disease, and related disorders.[1]
| Metric | Value |
|---|---|
| Total tracked trials (DNA repair mods) | ~50 |
| Active trials (recruiting/active) | ~15 (30%) |
| Preclinical programs | ~40 |
| Clinical-stage programs | ~10 (20%) |
DNA damage repair in neurodegeneration spans several key mechanistic categories:
Target: PARP1, PARP2
PARP inhibitors have shown neuroprotective effects in preclinical models of Alzheimer's Disease and Parkinson's Disease by reducing DNA damage accumulation and improving mitochondrial function.[2]
Key Programs:
Targets: OGG1, XRCC1, Pol beta
BER is the primary pathway for repairing oxidative DNA damage, which accumulates in aging neurons. Enhancement of BER is a promising therapeutic strategy.[3]
Key Programs:
The HR pathway is critical for repairing double-strand breaks. Dysfunction in neuronal HR contributes to genomic instability in neurodegeneration.[4]
Key Programs:
ATM and ATR are key DNA damage response kinases that coordinate repair, cell cycle arrest, and apoptosis. Modulating these kinases may protect neurons from genotoxic stress.[5]
Key Programs:
| Stage | Programs | Focus |
|---|---|---|
| Discovery/Preclinical | ~40 | BER enhancers, PARP modulators |
| Phase 1 | ~5 | PARP inhibitors, DNA repair supplements |
| Phase 2 | ~5 | PARP inhibitors, combination therapies |
| Phase 3 | ~0 | - |
| Company | Programs | Stage |
|---|---|---|
| Eli Lilly | PARP inhibitors | Phase 2 |
| Mitsubishi Tanabe | PARP modulators | Phase 2 |
| AbbVie | DNA repair research | Preclinical |
| Biogen | DDR modulators | Discovery |
| Institution | Focus Area |
|---|---|
| NIH (NIA, NINDS) | BER, PARP research |
| University of Pennsylvania | DNA repair in AD |
| Stanford University | ATM/ATR signaling |
| Cambridge University | Genomic instability in neurodegeneration |
DNA damage accumulation in neurons is a hallmark of aging and neurodegenerative diseases. DNA damage and the aging brain. Nature Reviews Neuroscience. 2020. ↩︎
PARP inhibition in neurodegenerative disease. PARP-1 and neuroprotection. Journal of Neurochemistry. 2011. ↩︎
Base excision repair in neurodegeneration. BER deficiency in Alzheimer's disease. DNA Repair. 2017. ↩︎
Homologous recombination and neuronal genome stability. BRCA1 in neuronal function. Nature Neuroscience. 2018. ↩︎
ATM/ATR signaling in neurodegeneration. DNA damage response in Parkinson's disease. Movement Disorders. 2020. ↩︎